Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Resequinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | WRN | Q14191 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resequinil SCHEMBL677466 | 1.00 | PIK3CD (0.57) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4890983 | 0.89 | PDE3B (0.54) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL678532 | 0.88 | PIK3CD (0.55) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4887297 | 0.84 | PIK3CD (0.52) | PIK3CDPIK3CBMAPTALDH1A1PTPN7 | |
| SCHEMBL4886299 | 0.82 | HSD17B10 (0.54) | MAPTALDH1A1PTPN7BLMWRN | |
| SCHEMBL4891258 | 0.79 | KDM4E (0.42) | MAPTALDH1A1PTPN7BLMWRN | |
| SCHEMBL16067423 | 0.73 | L3MBTL1 (0.72) | MAPTPKMHSD17B10KMT2ANPC1 | |
| SCHEMBL4883414 | 0.71 | ELANE (0.43) | PIK3CDPIK3CBMAPTALDH1A1HPGD | |
| SCHEMBL6437384 | 0.71 | JAK2 (0.46) | ALDH1A1PDE3BPDE3AKDM4ECLK2 | |
| SCHEMBL5752654 | 0.70 | NPC1 (0.39) | MAPTPKMHSD17B10KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250344963-A1 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIV OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2025-11-13 | — | — | US | disclosed |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4479365-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053573-A | Deuterated imidazole kesheng and methods of use thereof | 人类生物科学股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024211430-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-115645389-B | Application of compound ML1 and derivative thereof in improving activity and function of cerebral cortex | 刘晓栋 | 2024-10-01 | — | — | CN | disclosed |
| EP-3166610-B1 | METHODS FOR TREATING NEUROLOGIC DISORDERS | EIP PHARMA LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3368040-B1 | METHODS AND COMPOSITIONS FOR RECOVERY FROM STROKE | EIP PHARMA LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| WO-2022064429-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | VOCADLO DAVID (CA) | 2022-03-31 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRA1 8/4885GABRG2 14/4885GABRB3 9/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | GABRA1 2854/4885GABRG2 3641/4885GABRB3 1766/4885 |
| US-20250195477-A1 | DEUTERATED IDAZOXAN AND METHODS OF USE THEREOF | XDH, INA, SLC6A3 | GABRA1 119/4885GABRG2 369/4885GABRB3 373/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | GABRA1 1638/4885GABRG2 2547/4885GABRB3 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.